FDA Approves KalVista Pharmaceuticals' Ekterly as First Oral On-Demand Therapy for Hereditary Angioedema; DRI Healthcare Trust Increases Investment to $127 Million
Reuters
Jul 08, 2025
FDA Approves KalVista Pharmaceuticals' Ekterly as First Oral On-Demand Therapy for Hereditary Angioedema; DRI Healthcare Trust Increases Investment to $127 Million
DRI Healthcare Trust has announced that the U.S. Food and Drug Administration (FDA) has granted approval for Ekterly® (sebetralstat), developed by KalVista Pharmaceuticals, as the first and only oral on-demand therapy for treating acute attacks of hereditary angioedema $(HAE)$ in patients aged 12 years and older. This approval marks a significant advancement for those suffering from this rare genetic disorder characterized by severe swelling. As part of a financial arrangement, DRI Healthcare is entitled to a tiered royalty on the worldwide net sales of Ekterly. Additionally, KalVista has opted to receive further funding, increasing DRI Healthcare's total investment to $127 million, enhancing the financial collaboration between the two organizations.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DRI Healthcare Trust published the original content used to generate this news brief via CNW (Ref. ID: C2801) on July 08, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.